PRQR
ProQR Therapeutics N.V.Healthcare·Biotechnology
$1.58
$166M market cap
Revenue
$6.7M
Free Cash Flow
$-27.0M
Rev Growth
+0.0%
FCF Margin
-402.3%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platfo
2-Year Price History
$1.56-15.7%
Quarterly Financials & Projections
Quarterly Waterfall (EUR M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 2.1 | -13.2 | -13.9 | -13.6 | -11.3 | -12.1 | -0.2 | 81.2 | 13.7 | 105.4 | -312.2% | -- | -- |
| Act | 2025-Q4 | 4.6 | -8.4 | -9.0 | -8.8 | -13.1 | -14.9 | -0.5 | 92.4 | 14.0 | 103.0 | -120.4% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.58
Market Cap$166M
Enterprise Value$75M
P/S Ratio21.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-402.3%
FCF Yield-18.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$6.7M
Net Income$-22.4M
Free Cash Flow$-27.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin-320.9%
Net Margin-334.4%
FCF Margin-402.3%
CapEx % of Revenue10.2%
SBC % of Revenue0.0%
ROIC-216.3%
WC Change % Rev33.6%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.8M
Days to Cover1.0
Change (vs Prior)-33.0%
Need at least 2 settlement dates for chart
Employees
Headcount166
Revenue / Employee$40,425
Gross Profit / Employee$32,123
Cash Runway
36.1months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
36.7%(+1.2% YoY)
60 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.4%(+0.0% YoY)
4 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.0% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $10.1M | $2.70 | +$0 | −$3.0M | -0.1% | $64.61B |
| Privium Fund Management B.V. | $8.9M | $1.72 | +$177K | +$780K | +1.1% | $480M |
| Aberdeen Group plc | $5.4M | $1.61 | +$593K | +$2.4M | -0.6% | $61.88B |
| Affinity Asset Advisors, LLC | $4.0M | $2.43 | +$0 | −$1.3M | +0.6% | $1.60B |
| Sio Capital Management, LLC | $3.2M | $2.61 | −$339K | −$162K | -1.2% | $694M |
| DAFNA Capital Management LLC | $2.5M | $1.84 | +$0 | +$0 | -5.3% | $434M |
| Kynam Capital Management, LP | $2.5M | $2.65 | +$0 | −$298K | +0.5% | $1.58B |
| Ikarian Capital, LLC | $2.4M | $2.51 | +$0 | +$2.4M | -8.8% | $698M |
| MORGAN STANLEY | $2.1M | $1.79 | −$109K | −$136K | -0.3% | $1.65T |
| PLATINUM INVESTMENT MANAGEMENT LTD | $2.0M | $2.65 | +$0 | −$490K | +0.1% | $397M |
| TWO SIGMA INVESTMENTS, LP | $1.5M | $2.16 | +$129K | +$999K | -0.9% | $117.03B |
| Point72 Asset Management, L.P. | $1.2M | $2.61 | −$94K | +$9K | +0.9% | $54.88B |
| CITADEL ADVISORS LLC | $1.1M | $1.92 | +$195K | −$187K | -0.4% | $138.22B |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $1.0M | $2.02 | +$0 | +$1.0M | +1.4% | $58.02B |
| Walleye Capital LLC | $984K | $2.41 | +$26K | +$168K | -14.9% | $15.09B |
| M28 Capital Management LP | $972K | $3.70 | −$680K | −$680K | -7.9% | $53.8M |
| RAYMOND JAMES FINANCIAL INC | $885K | $1.98 | +$329K | +$719K | -0.0% | $322.69B |
| Monaco Asset Management SAM | $678K | $0.98 | −$16K | −$86K | +1.8% | $315M |
| BOOTHBAY FUND MANAGEMENT, LLC | $576K | $2.62 | +$0 | +$212K | -0.4% | $4.25B |
| UBS Group AG | $495K | $2.49 | −$798K | −$2.4M | -0.3% | $562.11B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.93%
avg per quarter
Holders (ex-self)
-0.92%
excl. this stock
Buyers (this Q)
-1.02%
11 buyers · $0.00B in
Sellers (this Q)
-1.73%
17 sellers · $0.01B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-16.1%
how holders react when this stock falls
On quiet Qs
-35.4%
−10% to +10% baseline
On rallies (+10%+)
-7.8%
how they react when this stock rises
Holders' portfolio flow this Q
+3.4%
inflows — adds are organic
Sellers' portfolio flow this Q
+3.0%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.3%
Holder mid (any stock)
-5.0%
Holder rally (any stock)
-8.9%
Biggest decreases this quarter
ArrowMark Colorado Holdings LLCexited−$2.4MUBS Group AG−$798Kα-0.3M28 Capital Management LP−$680Kα-7.9MILLENNIUM MANAGEMENT LLC−$390Kα-0.5Sio Capital Management, LLC−$339Kα-1.2MORGAN STANLEY−$109Kα-0.3Point72 Asset Management, L.P.−$94Kα+0.9FIFTH THIRD BANCORPexited−$61KPNC FINANCIAL SERVICES GROUP, INC.exited−$41KROYAL BANK OF CANADAexited−$20K
Top-5 holders · 55.7%
ADAGE CAPITAL PARTNERS GP, L.L.C.--
Privium Fund Management B.V.--
Aberdeen Group plc--
Affinity Asset Advisors, LLC--
Sio Capital Management, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RTW INVESTMENTS, LP—WELLINGTON MANAGEMENT GROUP LLP—FMR LLC—ADAGE CAPITAL PARTNERS GP, L.L.C.6.3MPrivium Fund Management B.V.5.5MPrivium Fund Management (UK) Ltd—GOLDMAN SACHS GROUP INC—JENNISON ASSOCIATES LLC—DRIEHAUS CAPITAL MANAGEMENT LLC—COWEN AND COMPANY, LLC—Opaleye Management Inc.—
Analyst Coverage
Analyst Coverage
Analyst Ratings
1
8
1
Strong Buy: 1Buy: 8Hold: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
33.4%retail+2.0pp
14.7%dark-0.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
ProQR Therapeutics: Milestone-Dependent Burn with Aggressive Dilution Cycles
Overall Risk
6/10
Fraud
3/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
5/10
Hidden Liabilities
2/10
Legal
2/10
Audit Warnings
3/10
Hidden Upside
7/10
Contextually Acceptable
7/10